5:56 PM
 | 
May 26, 2016
 |  BC Extra  |  Clinical News

Acucela's emixustat fails in AMD study

Acucela Inc. (Tokyo:4589) dropped Y1,000 (17%) to Y4,790 after it said emixustat (formerly ACU-4429) missed the primary endpoint of the Phase IIb/III S.E.A.T.T.L.E. study...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >